Royalty Report: Drugs, Therapeutic, Biotechnology – Collection: 29074


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Therapeutic
  • Biotechnology
  • cardiac
  • Cancer
  • Genome
  • Test/Monitoring
  • Diagnostic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29074

License Grant
The University granted the Licensee an exclusive, worldwide license, with the right to grant sublicenses, to make, have made, use, sell, offer to sell, import and export Licensed Products and to practice any Licensed Method.
License Property
The Invention is entitled eNOS Mutations Useful For Gene Therapy and Therapeutic Screening.
Field of Use
The Field means all cardiovascular-related therapeutic uses of the Licensed Intellectual Property that does not involve small molecule drug delivery.  Technology covers development, manufacture, use and sale of gene therapy products based on a phosphomimetic mutant of human endothelial nitric oxide synthase (eNOS) for the treatment of all cardiovascular diseases.

IPSCIO Record ID: 28042

License Grant
As part of Licensee's acquisition of the Licensor's portfolio of cardiovascular growth factor therapeutic assets, pursuant to a Technology Transfer Agreement entered into between the Licensor and the Licensee, Licensee acquired a portfolio of methods and compositions directed at the treatment of cardiovascular diseases. Licensee also has exclusive licenses to methods for introducing DNA to the heart and for improving heart muscle function, as well as to various biologics. The Licensee's resulting portfolio of cardiovascular product candidates and associated intellectual property include methods and genes applicable to the treatment of heart diseases, the promotion of healing, and the treatment of peripheral vascular disease. Among the product candidates we acquired  are Generx and Corgentin. Generx (alferminogene tadenovex) is a DNA-based, myocardial-derived growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. Angina, which is often felt as severe chest pain, can significantly limit patients’ mobility and quality of life and is a disorder that affects millions of adults in the United States and elsewhere.  In addition, we have secured the rights to Genvascor, a pre-clinical, DNA-based, endothelial nitric oxide synthase (eNOS) therapeutic.
License Property
Genvascor is being designed to induce production of nitric oxide and is directed at mediating the effects of multiple growth factors to enhance neovascularization and increased blood flow for the potential treatment of patients with critical limb ischemia due to advanced peripheral arterial occlusive disease (PAOD).
Field of Use
Licensee may elect to develop Genvascor alone or in collaboration with a development partner.

IPSCIO Record ID: 27156

License Grant
The Company hereby grants to InterMune the exclusive sublicense under the Genentech License Rights to develop, use, sell, offer for sale, import, make and have made Licensed Protein Products in the IG Field in the Territory.
License Property
Gene Therapy means the therapeutic or prophylactic treatment of a human being with (a) one or more oligonucleotides or nucleotide sequences.
Field of Use
IG Field means the administration to humans of Licensed Protein Product for the treatment or prevention of any human disease or condition, provided however, that IG Field shall not include (i) the administration to humans of Licensed Protein Product for the treatment or prevention of any type of arthritis or cardiac or cardiovascular disease or condition or (ii) use of Licensed Protein Product for Gene Therapy.

Gene Therapy field means the administration to humans of Licensed Gene Product for Gene Therapy for the treatment or prevention of any human disease or condition, provided however, that Gene Therapy Field shall not include any treatment or prevention of any type of cardiac or cardiovascular disease or condition.  Immunology-based products.

IPSCIO Record ID: 299285

License Grant
University grants an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use and sell joint licensed products.
License Property
The University jointly owns and is a joint proprietor of certain intellectual property relating to the human BRCA-2 breast cancer gene.
Field of Use
The field of use means any and all applications and uses of the BRCA-2 breast cancer gene, including but not limited to all diagnostic and therapeutic applications.

IPSCIO Record ID: 3187

License Grant
As part of our purchase of Chrysalis Biotechnology, Inc. on August 5, 2004, the License Agreements between CBI and OrthoLogic for the development, use, and marketing of the therapeutic products utilizing Chrysalin (TP508) were replaced by a direct License Agreement between the Licensee and the University of Texas.  

Subsequently, Licensee entered into an Agreement whereby the University of Texas assigned to the Licensee certain patents previously exclusively Licensed to the Licensee.

License Property
Under this Agreement, the Licensee must pay the University of Texas royalties and subLicense fees and pay various other fees in connection with filing and maintaining Chrysalin-related patents.

Chrysalin has been patented in the United States and in some other countries for a number of methods of use, including cardiovascular indications.  

A composition of matter patent covering European countries expired in 2007 and the corresponding United States patent expired in 2011.  Our other patents for Chrysalin expire between 2021 and 2024.

On January 20, 2012, the Licensee announced the intent to cease all activities related to the development of Chrysalin and to return the patent and other intellectual property we own related to Chrysalin to the original licensor.

Field of Use
Chrysalin (TP508), a novel synthetic 23-amino acid peptide, is believed to produce angiogenic and other tissue repair effects in part by 1) activating or upregulating endothelial nitric oxide synthase (eNOS); 2) cytokine modulation resulting in an anti-inflammatory effect; 3) inhibiting apoptosis (programmed cell death); and 4) modulating angiogenic factors.  It may have therapeutic value in diseases associated with endothelial dysfunction.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.